BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 31046611)

  • 1. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
    Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
    Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
    Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
    J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
    Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
    AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
    Zuckerman AD; Douglas A; Whelchel K; Choi L; DeClercq J; Chastain CA
    PLoS One; 2019; 14(11):e0225434. PubMed ID: 31751399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.
    Shafran SD
    Clin Infect Dis; 2015 Oct; 61(7):1127-34. PubMed ID: 26060286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C treatment initiation in HIV-HCV coinfected patients.
    Cotte L; Pugliese P; Valantin MA; Cuzin L; Billaud E; Duvivier C; Naqvi A; Cheret A; Rey D; Pradat P; Poizot-Martin I;
    BMC Infect Dis; 2016 Jul; 16():345. PubMed ID: 27450098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination.
    Du P; Jung J; Kalidindi Y; Farrow K; Riley T; Whitener C
    J Public Health Manag Pract; 2022 Mar-Apr 01; 28(2):130-134. PubMed ID: 32011599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
    Sikavi C; Najarian L; Saab S
    Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection.
    Yin X; Kong L; Du P; Jung J
    AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
    Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
    Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
    Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
    Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Insurance and Initiation of Direct-Acting Antivirals for Hepatitis C in US Women With Human Immunodeficiency Virus.
    Edmonds A; Haley DF; Edwards JK; Ramirez C; French AL; Tien PC; Plankey M; Sharma A; Augenbraun M; Seaberg EC; Workowski K; Alcaide ML; Albrecht S; Adimora AA
    Clin Infect Dis; 2023 Jul; 77(2):258-264. PubMed ID: 37021689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
    Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
    HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.